The global epidemic of Alzheimer disease (AD) is worsening, and no approved treatment
can revert or arrest progression of this disease. AD pathology is characterized by the …

Alzheimer's disease is a devastating neurodegenerative disorder with no cure. Countless
promising therapeutics have shown efficacy in rodent Alzheimer's disease models yet failed …

Alzheimer's disease (AD) is heterogenous at the molecular level. Understanding this
heterogeneity is critical for AD drug development. Here we define AD molecular subtypes …

APOE4 is the strongest genetic risk factor associated with late-onset Alzheimer's disease
(AD). To address the underlying mechanism, we develop cerebral organoid models using …

Sporadic Alzheimer's disease (AD) exclusively affects elderly people. Using direct
conversion of AD patient fibroblasts into induced neurons (iNs), we generated an age …

Alzheimer's disease (AD) is an aging-related neurological disorder characterized by
synaptic loss and dementia. Wnt/β-catenin signaling is an essential signal transduction …

Human pluripotent stem cells (hPSCs) and three-dimensional organoids have ushered in a
new era for disease modeling and drug discovery. Over the past decade, significant …

Adult neurogenesis, the process by which neurons are generated in certain areas of the
adult brain, declines in an age-dependent manner and is one potential target for extending …

Directed neuronal differentiation of human pluripotent stem cells (hPSCs), neural
progenitors, or fibroblasts using transcription factors has allowed for the rapid and highly …

Background Increased total tau (t-tau) in cerebrospinal fluid (CSF) is a key characteristic of
Alzheimer's disease (AD) and is considered to result from neurodegeneration. T-tau levels …